EWA
ACAD icon

EverSource Wealth Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

EverSource Wealth Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$36.9K Sell
1,460
-442
-23% -$9.72K ﹤0.01% 1976
2026
Q1 		$42.3K Buy
1,902
+461
+32% +$11K ﹤0.01% 2021
2025
Q4 		$38.5K Buy
1,441
+258
+22% +$6.17K ﹤0.01% 1933
2025
Q3 		$25.2K Buy
1,183
+215
+22% +$5.08K ﹤0.01% 2186
2025
Q2 		$20.9K Sell
968
-717
-43% -$13.3K ﹤0.01% 2254
2025
Q1 		$28K Buy
1,685
+815
+94% +$14.8K ﹤0.01% 1511
2024
Q4 		$16K Buy
870
+571
+191% +$9.22K ﹤0.01% 1748
2024
Q3 		$4.6K Sell
299
-59
-16% -$984 ﹤0.01% 2262
2024
Q2 		$6.81K Buy
358
+238
+198% +$3.84K ﹤0.01% 2073
2024
Q1 		$2.01K Buy
120
+98
+445% +$2.43K ﹤0.01% 2382
2023
Q4 		$689 Buy
22
+1
+5% +$24 ﹤0.01% 2463
2023
Q3 		$438 Hold
21
– – ﹤0.01% 2403
2023
Q2 		$503 Buy
+21
New +$467 ﹤0.01% 2354

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

EverSource Wealth Advisors's ACAD Position: Q2 2026 in Review

EverSource Wealth Advisors reduced its Acadia Pharmaceuticals (ACAD) stake by 23% in Q2 2026, selling an estimated $9.72K and leaving 1,460 shares worth $36.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1976.

EverSource Wealth Advisors first reported a position in ACAD in Q2 2023 and has held it in 13 quarters since. The position peaked at $42.3K in Q1 2026. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • EverSource Wealth Advisors held 1,460 shares of Acadia Pharmaceuticals worth $36.9K as of Q2 2026.
  • EverSource Wealth Advisors sold 442 Acadia Pharmaceuticals shares in Q2 2026, an estimated $9.72K.
  • Acadia Pharmaceuticals made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #1976 holding.
  • EverSource Wealth Advisors first reported a position in Acadia Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
  • EverSource Wealth Advisors's Acadia Pharmaceuticals position peaked at $42.3K in Q1 2026.
  • 354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.